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Clec4A4 is a regulatory receptor for dendritic cells
that impairs inﬂammation and T-cell immunity
Tomofumi Uto1,*, Tomohiro Fukaya1,*, Hideaki Takagi1, Keiichi Arimura1,2, Takeshi Nakamura1,3, Naoya Kojima4,
Bernard Malissen5 & Katsuaki Sato1,6
Dendritic cells (DCs) comprise several subsets that are critically involved in the initiation and
regulation of immunity. Clec4A4/DC immunoreceptor 2 (DCIR2) is a C-type lectin
receptor (CLR) exclusively expressed on CD8a conventional DCs (cDCs). However, how
Clec4A4 controls immune responses through regulation of the function of CD8a cDCs
remains unclear. Here we show that Clec4A4 is a regulatory receptor for the activation of
CD8a cDCs that impairs inﬂammation and T-cell immunity. Clec4a4 /CD8a cDCs
show enhanced cytokine production and T-cell priming following Toll-like receptor
(TLR)-mediated activation. Furthermore, Clec4a4 / mice exhibit TLR-mediated
hyperinﬂammation. On antigenic immunization, Clec4a4 / mice show not only augmented
T-cell responses but also progressive autoimmune pathogenesis. Conversely, Clec4a4 /
mice exhibit resistance to microbial infection, accompanied by enhanced T-cell responses
against microbes. Thus, our ﬁndings highlight roles of Clec4A4 in regulation of the function of
CD8a cDCs for control of the magnitude and quality of immune response.
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D
endritic cells (DCs) are essential antigen (Ag)-presenting
cells (APCs) linking innate and adaptive immunity, which
comprise heterogeneous subsets, functionally classiﬁed
into conventional DCs (cDCs) and plasmacytoid DCs (pDCs)1–3.
DCs act as sentinels to sense the invading pathogens through a
variety pattern-recognition receptors (PRRs), including Toll-like
receptors (TLRs).
Most of the members of TLRs, except for TLR3, associate
myeloid factor88 (MyD88) on binding of the ligands, and
initiates the activation of various intracellular signalling cascades,
including interleukin (IL)-1 receptor-associated kinase 1/4
(IRAK1/4), tumour necrosis factor (TNF) receptor-associated
factor 6 (TRAF6), and inhibitor of nuclear factor kB (NF-kB)
kinase-b (IKK-b) and their downstream, which further
activate NF-kB and mitogen-activated protein kinases (MAPKs),
including ERK, JNK and p38, are involved in the secretion of
proinﬂammatory cytokines, while the activation of IKK-a and its
downstream interferon (IFN) regulatory factor (IRF)-7 are crucial
for the production of type I IFN (IFN-I) (refs 4–6).
The recognition of the ligands by TLR3 or TLR4 also causes
their recruitment of the adapters Toll/IL-1 receptor (IL-1R)
domain-containing adapter-inducing interferon (IFN)-b (TRIF),
which interacts with TANK-binding kinase 1 (TBK1) and
activates, and downstream IRF-3 for the production of IFN-I,
while TRIF also activates MAP kinases and NF-kB leading to the
production of proinﬂammatory cytokines4,5.
DCs process and present exogenous Ags to CD4þ T cells
through major histocompatibility complex class (MHC)
II-restricted pathway for induction of CD4þ effector
T (CD4þ Teff) cells7,8. DCs also prime CD8þ T cells mediated
by classical MHC I presentation pathway of endogenously
synthesized proteins and MHC I-dependent cross-presentation
pathway of exogenous Ags for the generation of cytotoxic
T lymphocytes (CTLs)7,8.
Mouse CD11cþ cDCs in lymphoid organs consist of two
major subsets, classiﬁed into CD8aþ cDCs (cDC1) mainly
residing in the T-cell zone and CD8a cDCs (cDC2) localizing
in the red pulp and marginal zone, including CD4þCD8a
cDCs and CD4CD8a cDCs, which may exert distinct
functions in immune responses1–3. CD8aþ DCs appear to
be specialized for the phagocytosis of dead cells and the
cross-presentation of cell-associated and soluble Ags to induce
strong CTL responses7–10. In contrast, CD8a cDCs are more
efﬁcient than CD8aþ DCs in MHC II-dependent presentation
pathway to initiate CD4þ T-cell responses7,11.
C-type lectin receptors (CLRs) have been known as PRRs
recognizing a wide variety of glycan structures present on
pathogens, commensals and self-glycoproteins using their
carbohydrate recognition domain (CRD) in their extracellular
portion, and the ligand binding of CLRs on the surface of
myeloid cells often induces their internalization and/or
intracellular signalling events12,13. Several CLRs act as
activation receptors that transduce intracellular signals via an
integral immunoreceptor tyrosine-based activation motif
(ITAM)-like motif within their cytoplasmic tails, or via
interaction with ITAM-bearing Fc receptor (FcR)g adaptor
molecules13,14. Other CLRs possess an immunoreceptor
tyrosine-based inhibition motif (ITIM) in their cytoplasmic
portions, and intracellular signalling from these CLRs
suppresses or paradoxically enhances cellular activation15–17.
DC subsets reportedly express unique repertoires of CLRs that
are involved in Ag internalization and the routing to MHC I
and II loading compartments, thereby inﬂuencing T-cell
responses7,18. In a steady state, DEC-205 and Clec9A are
predominantly expressed on CD8aþ DCs7,18. In contrast,
CD8a cDCs speciﬁcally express Clec4A4 (DCIR2) recently
found to be recognized by the 33D1 monoclonal antibody (mAb),
which has been widely utilized as a benchmark for the
detection of mouse cDCs7,19,20. Clec4A4 has the potential to
deliver negative signals due to the presence of an ITIM in its
cytoplasmic portion that possibly affects the cellular activation of
CD8a cDCs. However, the physiological role for Clec4A4 in the
regulation of immune responses through control of the function
of CD8a cDCs remains unclear because its function is poorly
characterized relative to those of other CLRs.
In this study, we show by characterizing Clec4A4-deﬁcient
mice that Clec4A4 acts as a unique regulatory CLR in the
context of TLR-mediated activation of CD8a cDCs. We further
demonstrate that DCIR2 plays a crucial role in the regulation of
innate and adaptive immune responses under inﬂammatory
conditions in vivo. Collectively, these ﬁndings indicate that
Clec4A4 provides ﬁne tuning of the function of major cDC
subsets to generate appropriate immune responses.
Results
Clec4A4 suppresses the function of cDCs. To address the
function of Clec4A4 in cDCs, bone marrow (BM)-derived DCs
(BMDCs) as well as cDC cell lines (DC2.4) (ref. 21), which did
not express of Clec4A4 on the cell surface (Supplementary
Fig. 1a,b), were transfected with a bicistronic retroviral vector
carrying an internal ribosome entry site followed by green
ﬂuorescent protein (IRES-GFP; mock-GFP) or C terminus FLAG-
tagged Clec4A4-IRES-GFP (Clec4A4-GFP) (Supplementary
Fig. 1a,b), and their production of cytokines was analysed after
stimulation with various TLR ligands. Following stimulation with
Pam3CSK4 (TLR1/TLR2 ligands), poly(I:C) (TLR3 ligand),
lipopolysaccharide (LPS; TLR4 ligand) or CpG-B (TLR9 ligand),
BMDCs or DC2.4-expressing Clec4A4-GFP showed a lower
production of IL-6 IL-12p40, IFN-b and TNF-a than BMDCs or
DC2.4-expressing mock-GFP (Fig. 1a; Supplementary Fig. 1c,d;
Supplementary Fig. 2a).
To address how Clec4A4 regulates the TLR-mediated cytokine
production in cDCs, we examined the signalling mechanism by
which the expression of Clec4A4 caused the reduced production
of cytokines in cDCs. BMDCs or DC2.4-expressing Clec4A4-GFP
showed lower phosphorylation of NF-kB p65 subunit, ERK,
JNK and p38 as well as IRF-3 or IRF-7 than BMDCs or
DC2.4-expressing mock-GFP after stimulation with LPS or
CpG-B (Fig. 1b; Supplementary Fig. 1e; Supplementary Fig. 2b).
We also investigated the activation status of the ITIM in
Clec4A4 after the ligations of TLRs and Clec4A4. The steady-state
phosphorylation of the ITIM in Clec4A4 as well as its association
with SHP-1 and SHP-2 was observed in BMDCs expressing
Clec4A4-GFP, while crosslinking of Clec4A4 with anti-FLAG
mAb, but not stimulation with LPS, enhanced its phosphorylation
status and recruitment of these phosphatases (Fig. 1c). We also
observed that tyrosine-speciﬁc phosphatase activity in the
immunoprecipitate with Clec4A4 was further enhanced following
crosslinking of Clec4A4 with anti-FLAG mAb (Fig. 1d).
Clec4A4 consists of 236 amino acid, in which Y68 to L236 or I5
to V10 correspond to the extracellular portion or the ITIM
sequence, respectively. To clarify the role of extracellular portion
or ITIM in the suppressive function of Clec4A4 on the activation
of cDCs, we generated BMDCs expressing Clec4A4 mutant
lacking extracellular portion (Clec4A4DY68–L236-GFP) or ITIM in
cytoplasmic tails (Clec4A4DI5–V10-GFP). Following stimulation
with LPS or CpG-B, there was no marked difference in the
TLR-mediated cytokine production among BMDCs expressing
mock-GFP, BMDCs expressing Clec4A4DY68–L236-GFP,
and BMDCs expressing Clec4A4DI5–V10-GFP (Fig. 1a;
Supplementary Fig. 2a), indicating that the inhibitory effect of
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Clec4A4 on the TLR-mediated activation of cDCs requires both
extracellular portion and ITIM in cytoplasmic tails.
Collectively, these results indicate that retroviral transfection of
Clec4A4 suppresses the TLR-mediated cytokine production
mediated through the impaired activation of the downstream
signalling cascades in cDCs.
CRD–glycan interactions mediate homotypic Clec4A4 binding.
To identify the ligands of Clec4A4, we created CLR fusion
protein, which consists of the extracellular domain of Clec4A4
and the Fc fragment of human immunoglobulin G (IgG)
(Clec4A4-huIgFc). As the CRD of the family of Clec4As
potentially recognizes oligosaccharide moieties17,22, we examined
whether Clec4A4-huIgFc would bind to neoglycolipids (NGL)
constructed with oligosaccharides and dipalmitoylphos-
phatidylglycerol (DPPG)23 as carrier lipid (Fig. 2a,b). Clec4A4-
huIgFc, but not huIgFc and Clec9A-huIgFc, exhibited a
more potent speciﬁc binding to mannotriose (Man3)-DPPG or
lacto-N-fucopentaose 3 (LNFP3 (Lewisx))-DPPG than DPPE
alone or lacto-N-tetraose (LNT)-DPPG. On the other hand,
the speciﬁc binding of Clec4A4-huIgFc, but not huIgFc and
Clec9A-huIgFc, to biantennary N-linked core pentasaccharide
(BNCP)-DPPG, which contains N-acetylglucosamine (GlcNAc)
and Man3 residues, was higher than Man3-DPPG. We
also observed that Clec4A4-huIgFc, but not huIgFc and
Clec9A-huIgFc, speciﬁcally bound to asialoganglioside-GM2
(asialo-GM2) consisting of N-acetylgalactosamine (GalNAc)
and lactocerebrosides was higher than that to lactocerebrosides.
As the CRD of SIGNR1 also reportedly recognizes several
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Figure 1 | Retroviral transduction of Clec4A4 suppresses the TLR-mediated activation of cDCs. (a) BMDCs expressing mock-GFP, Clec4A4-GFP,
Clec4A4N186Q-GFP, Clec4A4DY68–L236-GFP or Clec4A4DI5–V10-GFP were stimulated or not stimulated with the indicated LPS, and the production of
cytokines was measured by enzyme-linked immunosorbent assay (ELISA). Data are the mean±s.d. from three individual samples in a single experiment.
*Po0.01 compared with BMDCs expressing mock-GFP or among groups (analysis of variance (ANOVA), Bonferroni’s multiple comparison test).
(b) BMDCs expressing mock-GFP or Clec4A4-GFP were stimulated or not stimulated with LPS for the period indicated, at which time cells were lysed. Total
lysate was analysed using Ab speciﬁc for p65, ERK, JNK, p38 and IRF-3 or for phosphorylated versions of these proteins. (c,d) BMDCs expressing mock-
GFP or Clec4A4-GFP were stimulated or not stimulated with LPS in combination with or without crosslinking of Clec4A4 with anti-FLAG M2 mAb for
30min. (c) The immunoprecipitate with anti-FLAG M2 mAb was analysed using anti-phosphotyrosine (p-Tyr) mAb, anti-SHP-1 mAb, anti-SHP-2 mAb or
anti-FLAG M5 mAb. (d) The immunoprecipitate with anti-FLAG M2 mAb or control IgG was analysed for protein tyrosine phosphatase activity. Data are
the mean±s.d. from three individual samples in a single experiment. *Po0.01 compared with the immunoprecipitate with anti-FLAG M2 mAb obtained
from unstimuated cells (ANOVA, Bonferroni’s multiple comparison test). All data are representative of at least three independent experiments.
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oligosaccharide residues of glycan23, SIGNR1-huIgFc showed
higher speciﬁc binding to Man3-DPPG than DPPG alone,
whereas the binding of SIGNR1-huIgFc with BNCP-DPPG
or Lewisx-DPPG was comparable to that with Man3-DPPG or
LNT-DPPG. Furthermore, there was no different in the binding
of SIGNR1-huIgFc to lactocerebrosides and asialo-GM2.
Taken together, these results indicate that the CRD of Clec4A4
speciﬁcally recognizes D-mannose (Man), L-fucose (Fuc), GlcNAc
and GalNAc moieties on glycan.
We further examined whether Clec4A4-huIgFc directly bound
to DC2.4-expressing Clec4A4-GFP because the extracellular
domain of Clec4A4 possesses several predicted N-glycosylation
sites (Fig. 2c). While Clec4A4-huIgFc, but not huIgFc and
Clec9A-huIgFc, bound to DC2.4 and DC2.4-expressing mock-
GFP, the speciﬁc binding of Clec4A4-huIgFc to DC2.4-expressing
Clec4A4-GFP was signiﬁcantly higher than that to DC2.4 and
DC2.4-expressing mock-GFP, indicating that Clec4A4 interacts
with itself on cDCs. To a lesser degree, similar results
were observed in the binding of SIGNR1-huIgFc to
DC2.4, DC2.4-expressing mock-GFP and DC2.4-expressing
Clec4A4-GFP.
Since the self-interaction of Clec4A4 would be mediated by the
binding of the CRD with oligosaccharide resides on glycans,
and the N186 of Clec4A4 is a only N-glycosylation site in the
CRD (ref. 17), we therefore generated BMDCs expressing a
glycosylation mutant of Clec4A4 (Clec4A4N186Q-GFP) lacking the
N-glycosylation site in the CRD. The introduction of
Clec4A4N186Q-GFP displayed a lower inhibitory effect on the
capacity of BMDCs to secrete cytokines after stimulation with
LPS or CpG-B as compared with that of Clec4A4-GFP (Fig. 1a;
Supplementary Fig. 2a), suggesting that the N-glycosylation of
CRD is required for self-interaction of Clec4A4 for the
suppressive effect on the TLR-mediated activation of cDCs.
Clec4A4 inhibits the TLR-mediated activation of CD8a cDCs.
To investigate the physiological functions of Clec4A4 in the control
of the immune responses through regulation of the function of
CD8a cDCs, we created Clec4a4 / mice (Supplementary
Fig. 3a–e), which were viable and healthy. As expected, CD8a
cDCs from Clec4a4 / mice lacked cell surface expression of
Clec4A4 (Fig. 3a,b). Histological analysis of Spl obtained from
Clec4a4 / mice conﬁrmed that the expression of Clec4A4 was
not detected, while CD11cþ DCs were normally localized
(Fig. 3c). CD8a cDCs obtained from wild-type (WT) mice and
Clec4a4 / mice had similar expressions of MHC I (H-2Kb) and
MHC II (I-A/I-E) as well as CD11c and costimulatory molecules
(Fig. 3d,e) under steady-state conditions. We also observed similar
ability of CD8a cDCs between WT mice and Clec4a4 /
mice to activate CD4þ and CD8þ T cells using ovalbumin
(OVA)-speciﬁc T-cell receptor (TCR) transgenic OT-II CD4þ
T cells and OT-I CD8þ T cells (refs 6,24; Fig. 3f,g).
To address the inﬂuence of deﬁciency of Clec4A4 on the
functions of CD8a cDCs, we analysed the TLR-mediated
changes of CD8a cDCs from WT mice and Clec4a4 / mice.
Whereas the injection of CpG-B enhanced the expression of
MHC I, MHC II, and costimulatory molecules on CD8a cDCs,
and their ability to activate OT-II CD4þ T cells and OT-I CD8þ
T cells in WT mice, compared with those from untreated WT
mice, the expression levels of these molecules and their ability to
activate T cells were further enhanced in Clec4a4 / mice
(Fig. 3e–g; Supplementary Fig. 4).
Collectively, the deﬁciency of Clec4A4 promotes the TLR-
mediated upregulation of MHC and costimulatory molecules in
CD8a cDCs, leading to their enhancement of T-cell activation.
Because the induced expression of Clec4A4 suppresses TLR-
mediated cytokine production in cDCs, we compared the
cytokine production of CD8a cDCs between WT mice and
Clec4a4 / mice (Fig. 4). Clec4a4 / CD8a cDCs showed
higher secretion of IL-6, IL-12p40, IFN-b and TNF-a after
stimulation with Pam3CSK4, poly(I:C), LPS and CpG-B than WT
CD8a cDCs. We also observed that Clec4a4 / CD8a cDCs
showed greater phosphorylation of NF-kB p65 subunit, ERK,
JNK and p38 as well as IRF-3 or IRF-7 after stimulation with LPS
or CpG-B (Supplementary Fig. 5).
These results indicate that the deﬁciency of Clec4A4 enhances
the ability of CD8a cDCs to produce proinﬂammatory
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Figure 2 | Self-interaction of Clec4A4 through the binding of CRD and
glycans. (a) Schematic diagram of structures of the oligosaccharides in
NGL. Gal, D-galactose; Glc, D-glucose. (b) The binding of huIgFc, Clec4A4-
huIgFc, SIGNR1-huIgFc or Clec9A-huIgFc to glycans was measured by
ELISA. Data are the mean±s.d. from three individual samples in a single
experiment. *Po0.01 compared with DEEG or among groups (analysis of
variance (ANOVA), Bonferroni’s multiple comparison test). (c) The binding
of huIgFc, Clec4A4-huIgFc, SIGNR1-huIgFc or Clec9A-huIgFc to DC2.4,
DC2.4-expressing mock-GFP, and DC2.4-expressing Clec4A4-GFP was
analysed by ﬂow cytometry with anti-huIgFc-PE. Data are presented by a
dot plot, and numbers represent the proportion of the binding of huIgFc,
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data are representative of at least three independent experiments.
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cytokines and type I IFN, which is associated with the increased
activation of NF-kB, MAPKs and IRFs in response to TLR
ligands.
Clec4A4 suppresses the TLR-mediated inﬂammation. We
examined the roles of Clec4A4 in the TLR-mediated
inﬂammation in vivo. The application of Pam3CSK4, poly(I:C),
LPS or CpG-B caused serum secretion of IL-6, IL-12p40, IFN-b
and TNF-a in WT mice (Fig. 5a and Supplementary Fig. 6). On
the other hand, Clec4a4 / mice exhibited prominent elevation
in the serum production of these cytokines following injection
with various TLR ligands, compared with WT mice (Fig. 5a;
Supplementary Fig. 6). We also demonstrated that Clec4a4 /
mice showed more susceptiblity to lethality induced by microbial
peritonitis than WT mice, and this lethality was correlated with
the more marked secretion of serum proinﬂammatory cytokines
24 h following the administration of heat-killed Escherichia coli
(Fig. 5b,c).
We next compared the proportion of leukocytes in the spleen
between WT mice and Clec4a4 / mice under steady-state and
TLR ligand-induced inﬂammatory conditions (Supplementary
Fig. 7). In the steady-state conditions, Clec4a4 / mice
exhibited regular myeloid and lymphoid immune cell
compartments in the spleen. The administration of CpG-B to
WT mice increased the weight of spleen and the absolute number
of leukocytes, with elevated frequencies of CD11cB220þ B cells
and CD11cþB220þ pDCs and a reduced proportion of
other leukocytes. On the other hand, Clec4a4 / mice showed
greater weight of spleen and more splenocytes than WT mice
after injection with CpG-B. Furthermore, Clec4a4 / mice
exhibited a higher frequency of CD11cB220þ B cells, and
lower frequencies of CD3þ T cells, CD4þ T cells and CD8þ
T cells than WT mice following injection with CpG-B.
Taken together, these results indicate that the deﬁciency of
Clec4A4 augments TLR-mediated inﬂammation in vivo.
Clec4a4 attenuates the responses of CD4þ T cells. We
examined how Clec4A4 controls CD4þ T-cell responses through
the regulation of the function of CD8a cDCs. In vitro analysis
revealed that Clec4a4 / CD8a cDCs displayed an enhanced
capacity to generate OVA-speciﬁc IFN-g-producing CD4þ
T cells (T helper 1; TH1 cells) and IL-17-producing CD4þ T cells
(TH17 cells) when compared with WT CD8a cDCs (Fig. 6a–d;
Supplementary Fig. 8a,b).
To determine the roles of Clec4A4 in the capacity of CD8a
cDCs to prime Ag-speciﬁc CD4þ T cells in vivo, OT-II CD4þ
T cells, which were labelled with carboxyﬂuorescein
diacetate-succinimidyl ester (CFSE), were adoptively transferred
into mice, and their division was monitored 3 days after
administration of soluble OVA protein under steady-state or
inﬂammatory conditions (Fig. 6e,f; Supplementary Fig. 8c). While
similar Ag-speciﬁc division of OT-II CD4þ T cells between
WT mice and Clec4a4 / mice was observed after systemic
injection of OVA protein, Clec4a4 / mice exhibited the
enhancement of this response compared with WT mice following
the administration of OVA protein plus various TLR ligands.
We also compared the responses of Ag-speciﬁc CD4þ T cells
between WT mice and Clec4a4 / mice. At 14 days after
immunization with OVA protein and complete Freund’s adjuvant
(CFA), CD4þ T cells from Clec4a4 / mice showed more
prominent proliferation and secretion of IFN-g as well as the
generation of TH1 cells than those from WT mice (Fig. 6g–i).
Similarly, Clec4a4 / mice had the enhanced Ag-speciﬁc
proliferation and production of IFN-g and IL-17 as well as the
augmented generation of TH1 cells and TH17 cells compared with
WT mice following immunization with CpG-B plus OVA
(Supplementary Fig. 8d–f).
Taken together, these results indicate that the deﬁciency of
Clec4A4 potentiates the responses of Ag-speciﬁc CD4þ Teff cells
in vivo.
Clec4A4 reduces the responses of CD8þ T cells. We addressed
the inﬂuence of the deﬁciency of Clec4A4 on the capacity of
CD8a cDCs to activate of CD8þ T cells through the
cross-presentation of soluble Ag in vivo. On immunization with
OVA protein plus various TLR ligands, Clec4a4 / mice
displayed signiﬁcant enhancement of Ag-speciﬁc proliferation of
adoptively transferred OT-I CD8þ T cells compared with WT
mice (Fig. 7a,b; Supplementary Fig. 9a).
To examine the inﬂuence of the deﬁciency of Clec4A4 on the
induction of CTLs through the cross-presentation of soluble Ag,
we quantiﬁed the generation of Ag-speciﬁc CD8þ T cells based
on binding with the MHC I-OVA tetramer and intracellular
expression of IFN-g 6 days after immunization with OVA protein
combined with various TLR ligands and anti-CD40 mAb
(Fig. 7c–f; Supplementary Fig. 9b,c). Clec4a4 / mice had more
marked augmentation in the induction of MHC I-OVA
tetramerþCD44highCD8þ T cells and CD8þ IFN-gþ T cells
than WT mice.
Collectively, these results indicate that the deﬁciency of
Clec4A4 promotes the ability of CD8a cDCs to activate
CD8þ T cells through cross-presentation in vivo.
Clec4A4 ameliorates experimental autoimmune encephalitis.
We assessed the impact of the deﬁcency of Clec4A4 on the
initiation and progression of experimental autoimmune
encephalitis (EAE). Immunization of WT mice with myelin
oligodendrocyte glycoprotein35–55 peptide (MOGp) together with
CFA elicited EAE (Fig. 8a,b), which was accompanied by the
generation of Ag-speciﬁc CD4þ T-cell proliferation, and the
induction of TH1 cells and TH17 cells following ex vivo
recall antigenic stimulation, as well as the secretion of anti-
MOGp-speciﬁc IgG (Fig. 8c–g). In contrast, Clec4a4 / mice
showed more progressive development of EAE than WT mice
(Fig. 8a,b). Furthermore, Clec4a4 /mice displayed a higher
Ag-speciﬁc proliferation of CD4þ T cells than WT mice (Fig. 8c).
Indeed, CD4þ T cells from Clec4a4 / mice not only exhibited
more potent production of IFN-g and IL-17 but also had a higher
frequency of TH1 cells and TH17 cells than WT mice (Fig. 8d–f).
On the other hand, Clec4a4 / mice showed higher production
of anti-MOGp-speciﬁc IgG than WT mice (Fig. 8g).
Collectively, the deﬁciency of Clec4A4 aggravates the
development of T-cell-mediated autoimmune disease through
the excessive activation of CD8a cDCs.
Clec4A4 suppresses host protection against bacterial infection.
To determine the role of Clec4A4 in the host protection against
bacterial infections through the regulation of the function of
CD8a cDCs, we examined the host protective immune
responses against Listeria monocytogenes expressing OVA
(LM-OVA)25. While WT mice succumbed to bacterial
infection within 11 days, Clec4a4 / mice showed an
enhanced survival rate (Po0.01), which was associated with
signiﬁcant reduction in splenic bacterial burden, and prominent
elevation in serum productions of IL-6, IL-12p40 and IFN-g
(Supplementary Fig. 10a–c). Furthermore, Clec4a4 / mice
displayed the enhanced anti-bacterial responses of CD4þ T cells
following bacterial infection when compared with WT mice
(Supplementary Fig. 10d–f).
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Collectively, these results indicate that the deﬁciency of
Clec4A4 promotes anti-bacterial protective immune responses
through the augmentation of the function of CD8a cDCs
unless the inﬂammation causes the microbial septic shock.
Discussion
As described in this manuscript, our biochemical and genetic
results clearly demonstrate that Clec4A4 acts as a unique
‘regulatory CLR’ for the TLR-mediated activation of CD8a
cDCs that is critical for control of the magnitude and quality of
innate and adaptive immune responses. To our knowledge, our
ﬁndings are the ﬁrst describing that Clec4A4 known as a
DC-speciﬁc surface marker molecule suppresses the cellular
activation and maturation of CD8a cDCs, while most PRRs
expressed on DCs reportedly act as activation receptors1–3.
Furthermore, the Clec4A4-mediated regulation of CD8a cDCs
was shown to impact on immune responses in vivo.
The family of Clec4As is the only group of classical CLRs with
an ITIM in their cytoplasmic tail17,26. In sharp contrast to
Clec4A4, Clec4A2 (DCIR1) is expressed on a various immune
cells, such as B cells, monocytes/macrophages and DCs17,22,27. It
has been shown that the triggering of human Clec4A with speciﬁc
mAb not only elicits its internalization to endosomal/lysosomal
compartments leading to Ag presentation, but also results in
inhibition of the TLR9-mediated secretion of type I IFN on
human pDCs and the TLR8-mediated production of
proinﬂammatory cytokines on human cDCs, although which
signalling pathway is elicited after the ligation of Clec4A, leading
to the inhibition of TLR signalling, remains unresolved17,28,29.
Here we show that retroviral transfection of Clec4A4 into cDCs
impairs TLR-mediated cytokine production, possibly through
suppression of the activation of MyD88- or TRIF-dependent
activation of NF-kB, MAPKs and IRFs. Consistently, deﬁciency of
Clec4A4 speciﬁcally leads to the hyperresponsiveness of CD8a
cDCs to various TLR ligands for the secretion of cytokines
mediated by the augmented activation of NF-kB, MAPKs and
IRFs. Thus, our ﬁndings strongly suggest that Clec4A4 generates
an inhibitory signal for the TLR-mediated downstream cascades
to abrogate the activation of CD8a cDCs.
Previous studies have shown that the phosphorylated ITIM in
human Clec4A is able to interact with SHP-1 and SHP-2 using
pervanadate treatment30 or a peptide containing the
phosphorylated form of ITIM31, although their physiological
relevance remains unclear. We demonstrated that Clec4A4
mutant lacking ITIM in cytoplasmic tails had no inhibition on
the TLR-mediated cytokine production in cDCs, suggesting that
the inhibitory effect of Clec4A4 on the TLR-mediated activation
of cDCs directly involves the ITIM-mediated intracellular
signalling. Furthermore, Clec4A4 constitutively associated with
SHPs under steady-state phosphorylation of its ITIM, and the
ligation of Clec4A4 not only potentiated its phosphorylation
status, but also enhanced the recruitment of these phosphatases
and their functions. As the deﬁciency of SHPs reportedly
ampliﬁed the TLR-mediated downstream signalling cascades for
the enhanced production of IFN-I and proinﬂammatory
cytokines, SHP-1 has been shown to block the MyD88-
dependent cytokine secretion by suppressing the activation of
NF-kB, MAPK, IRAK1, IKK-a and IKK-b mediated through
directly binding and dephosphorylating them, whereas SHP-2 has
been shown to inhibit the TLR3/4-mediared cytokine production
in TRIF-dependent signalling due to the direct interaction with
TBK1 (refs 4,32–34). Therefore, the molecular inhibitory
machinery in the Clec4A4-mediated suppression of TLR
ligand-induced cytokine production could involve the
association of SHP-1 or SHP-2 with the phosphorylated ITIM
in Clec4A4, leading to the impairment of MyD88- or
TRIF-dependent activation of the downstream signalling
pathway.
Analysis of Clec4A4 mutant lacking extracellular portion
suggests that the excessive expression of membrane-anchored
ITIM might be insufﬁcient for the suppressive effect on the
TLR-mediated activation of cDCs when extracellular portion of
Clec4A4 is lacking. Furthermore, a glycosylation mutant
of Clec4A4 lacking the N-glycosylation site in the CRD, which
possibly prevented the formation of self-interaction, reduced the
inhibitory effect. Thus, the self-interaction of Clec4A4 in cis
and/or trans through the binding of its CRD with oligosaccharide
resides on glycans could be required for the suppressive effect on
the TLR-mediated activation of cDCs.
Similar to the proposed concept for the masking of Siglecs35,
the potential interaction of Clec4A4 with glycans present on
Clec4A4 itself and cis ligands existed on neighbouring
glycoproteins could occupy its CRD because we clearly
demonstrated that the steady-state phosphorylation of ITIM in
Clec4A4 in cDCs. Indeed, we showed that the soluble form of
Clec4A4 speciﬁcally bound to Man, Fuc, GlcNAc and GalNAc
moieties on glycans and Clec4A4-expressing cDC transfectants,
while it also bound to their control transfectants to a lesser extent.
Thus, it is intriguing to hypothesize that Clec4A4 constitutively
associates with itself in addition to other adjacent glycoproteins
(for example, SIGNR1) mediated through the binding of CRD
with oligosaccharide resides on glycans, and the inhibitory
signalling via ITIM in Clec4A4 could potentially occur under
steady-state conditions, resulting in lowering of the
responsiveness of CD8a cDCs to TLR-mediated activation.
Different from our observation on the suppressive role of
Clec4A4 in the TLR-mediated activation of CD8a cDCs, the
deﬁciency of Clec4A2 reportedly did not affect the response of
BMDCs to LPS stimulation36, despite the fact that these two
Clec4As share similar extracellular domain and cytoplasmic
portions. It remains unclear how distinct Clec4A4s lead
to different cellular responses, the kinetics, afﬁnity and
speciﬁcity of glycan binding, or the valency of engagement of
Figure 3 | Deﬁciency of Clec4A4 modulates TLR-mediated activation of CD8a cDCs. (a,b) The expression of Clec4A4 and cell surface molecules on
splenocytes (a) and CD11cþ DCs (b) obtained from WTmice and Clec4a4 / mice was analysed by ﬂow cytometry. Data are presented by a dot plot, and
numbers represent the proportion in each quadrant. (c) Immunoﬂuorescent microscopic analysis was performed on frozen horizontal sections. Sections were
stained for CD19 (green), CD3e (blue) and Clec4A4 (red) or CD11c (red). (d) The expression of Clec4A4 and cell-surface molecules on CD8a cDCs
obtained from WTmice and Clec4a4 / mice was analysed by ﬂow cytometry. Data are presented by a histogram, and numbers represent mean
ﬂuorescence intensity (MFI). (e) WTmice (n¼6) and Clec4a4 / mice (n¼ 6) were injected with or without CpG-B, and CD8a cDCs were obtained 24h
after injection. The expression of cell surface molecules on CD8a cDCs was analysed by ﬂow cytometry. Data are MFI±s.d. from six individual samples in a
single experiment. (f,g) WTmice (n¼ 6) and Clec4a4 / mice (n¼ 6) were not injected (left panel) or injected (right panel) with CpG-B, and CD8a cDCs
were obtained 24h after injection. CD45.1þOT-II CD4þ Tcells (f) or CD45.1þOT-I CD8þ Tcells (g) were cultured with CD8a cDCs (104) obtained from
WTmice and Clec4a4 / mice in the presence or absence of OVA323–339 peptide (1mM; f) or OVA257–264 peptide (1 nM; g), and the proliferation was
measured by [3H]thymidine incorporation. Data are the mean±s.d. from six individual samples in a single experiment. *Po0.01 compared with WTmice
(analysis of variance (ANOVA), Bonferroni’s multiple comparison test). All data are representative of at least three independent experiments.
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each Clec4A, as well as how cell-type-speciﬁc expression
potentially accounts for the distinct signalling through the
ITIM-mediated regulation of cell function.
Whereas various immune cells, including DCs and non-
haematopoietic cells, have been reported to express various TLRs
to respond to each ligand37, the contribution of CD8a cDCs to
the TLR-mediated responses and their regulatory mechanism
in vivo remains unclear. In line with the augmented TLR-
mediated cytokine production by Clec4a4 / CD8a cDCs,
analysis of in vivo responsive to TLR ligands and bacterial
peritonitis revealed that Clec4a4 / mice exhibited
hyperinﬂammatory response associated with the excessive
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production of cytokines. These ﬁndings suggest that Clec4A4
increases the threshold of responsiveness of CD8a cDCs to
TLR ligands as well as other pathogen-associated molecular
patterns to prevent excessive detrimental to inﬂammation.
Although there have been several reports describing the role for
CD8a cDCs in the induction of the responses of CD4þ T cells
in vivo by the Ag targeting to this DC subset via 33D1 mAb7,20,
how CD8a cDCs instruct and regulate the responses of CD4þ
T cells in vivo remains unclear. Our in vitro analysis showed
that the deﬁciency of Clec4A4 promoted the ability of CD8a
cDCs to generate Ag-speciﬁc TH1/TH17 cells. Furthermore, the
deﬁciency of Clec4A4 not only enhanced Ag-speciﬁc priming
of CD4þ T cells but also augmented CD4þ Teff-cell responses
in vivo. These observations strongly suggest that the deﬁciency of
Clec4A4 leads to enhancement of the capacity of CD8a cDCs
to upregulate the expression of MHC and costimulatory
molecules, and to produce cytokines after the ligation of
TLRs, resulting in the promoted development of CD4þ Teff
cells from naive CD4þ T cells in vivo under inﬂammatory
conditions. Thus, Clec4A4 could regulate APC function of
CD8a cDCs for tight control of the direction of the responses
of CD4þ Teff cells in vivo.
CD8aþ cDCs have reportedly shown to be superior to
CD8a cDCs to prime CD8þ T cells for the generation of
CTL response through cross-presentation, possibly owing to the
differences in expression of proteins associated with Ag
processing for MHC I presentation1,7,8. Notably, the deﬁciency
of Clec4A4 caused a further increase in the priming of Ag-speciﬁc
CD8þ T cells and induction of CTLs in vivo when soluble Ag was
immunized, demonstrating the potential cross-presentation
capacity of CD8a cDCs for the efﬁcient generation of CTLs.
Therefore, Clec4A4 could strictly suppress the TLR-mediated
ampliﬁcation of the expression of several proteins involved in
cross-presentation to activate CD8þ T cells in CD8a cDCs
under pathophysiological conditions.
It has been shown that Clec4a2 (Dcir1) / mice exhibited an
exacerbation of the pathogenesis in collagen-induced arthritis
(CIA), possibly due to the excessive expansion of CD11cþ DCs36.
Furthermore, the expression of CD80, CD86 and MHC II on
CD11cþ DCs in CIA-induced Clec4a2 / mice was at a normal
level for their steady-state conditions, indicating that DCIR1
could not be involved in the maturation and activation of
CD11cþ DCs36. On the other hand, our results demonstrated
that Clec4a4 /mice displayed progression of the pathogenesis
of EAE, which is accompanied by the enhanced generation of
MOG-speciﬁc TH1 cells and TH17 cells as well as massive
production of anti-MOGp-speciﬁc IgG. Therefore, in sharp
contrast to the suppressive role of Clec4A2 in the expansion of
CD11cþ DCs for the development of autoimmune diseases,
Clec4A4 could speciﬁcally downregulate the maturation and
activation of CD8a cDCs rather than their expansion, leading
to impairment of the pathogenic responses of CD4þ Teff cells,
which is responsible for amelioration of the pathogenesis of
autoimmune diseases.
While cDCs have reportedly been involved in host defenses
against bacterial infections mediated through the recognition of
pathogen-associated molecular patterns by several activating
PRRs5,38, the role of CLRs in the abortive activation of cDCs
leading to the inhibition of anti-microbial immunity remains to
be understood. On bacterial infection, the deﬁciency of Clec4A4
not only led to the augmentation of anti-bacterial CD4þ Teff
cell-responses, but also displayed the prominent elimination of
the invaded bacteria, resulting in the reduction of the mortality.
These observations led us to hypothesize that the interaction of
the CRD of Clec4A4 with the glycan present on microbes also
cause the impaired activation of CD8a cDCs, which hampers
anti-microbial host defense.
In conclusion, we described that Clec4A4 constitutes a CLR
endowed with critical negative regulatory function in CD8a
cDCs, in which it prevents the induction of exacerbated
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Figure 4 | Deﬁciency of Clec4A4 enhances the ability of CD8a cDCs to
produce cytokines in response to TLR ligands. CD8a cDCs obtained
from WTmice and Clec4a4 / mice were stimulated or not stimulated
with Pam3CSK4 (a), poly(I:C) (b), LPS (c) and CpG-B (d), and the
production of cytokines was measured by ELISA. Data are the mean±s.d.
from three individual samples in a single experiment. *Po0.01 compared
with WTmice (analysis of variance (ANOVA), Bonferroni’s multiple
comparison test). All data are representative of at least three independent
experiments.
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inﬂammation and pathological T-cell responses, and therefore
maintains immune homeostasis and prevents immunopathogen-
esis. Conversely, Clec4A4 also contributes to the subversion of
anti-microbial host protective immune responses mediated
through the abortive activation of CD8a cDCs, which is linked
to the microbial evasion from immune surveillance. Thus, our
ﬁndings proposed the concept that ‘regulatory CLR’ binding to
endogenous ligands on cDCs and pathogens plays an crucial role
in immune homeostasis and host defense. Targeting this unique
CLR with antibody (Ab) may constitute new therapies for
autoimmune and inﬂammatory disorders as well as infectious
diseases and cancer.
Methods
Mice. The following 8- to 12-week-old female mice were used in this study:
C57BL/6 mice (Japan Clea), B6.CD45.1þOT-I TCR transgenic mice harbouring
OVA-speciﬁc CD8þ T cells6,24, and B6.CD 45.1þOT-II TCR transgenic mice
harbouring OVA-speciﬁc CD4þ T cells6,24, and B6.Clec4a4 / mice as described
below. All mice were bred and maintained in speciﬁc pathogen-free conditions in
the animal facility at University of Miyazaki in accordance with institutional
guidelines of the Animal Experiment Review Board.
Generation of Clec4a4 / mice. The targeting vector for Clec4a4 /mice was
constructed in the pBluescript vector by using a 4.0-kb genomic fragment (left arm)
upstream of Clec4a4 exon 1 and a 2.0-kb genomic fragment (right arm) down-
stream of exon 2 cloned from a modiﬁed bacterial artiﬁcial chromosome clone,
RP23-265M17 (Children’s Hospital Oakland Research Institute), containing the
complete Clec4a4 gene (gene symbol Clec4a4). The left arm was generated by PCR
using the following oligonucleotides: left arm forward (50-CGCCTCGAGGTGATG
AATCAAAGATTTAACAGAATGTA-30) and left arm reverse (50-CGCGTCGACT
TCAAGAAAAGACCTGCCTCCCTCAGAAAGCACAA-30). The 4.0-kb PCR
fragment was digested with XhoI and SalI, and ligated into each site of pBluescript.
The right arm was generated by PCR using the following oligonucleotides: right
arm forward (50-CGCGTCGACGTAAGTATCCTGCACACATCAATGGGCCT
TGTCTG-30) and right arm reverse (50-CGCACTAGTGTTCCTCAGAA
AATTGGACATATTACTAC-30), digested with SalI and SpeI, and ligated into each
site of the targeting vector. Each of the 50 and 30 primers was also tagged (indicated
in italics) with XhoI and SalI sites for the left arm or SalI and SpeI sites for the right
arm, respectively. A SalI restriction site was engineered in place of the start codon
in exon 1. The pIRES2-EGFP-loxP-Cre/Neor-loxP auto-deleter cassette39 was
cloned into the SalI site inserted into the targeting vector. Finally, the targeting
construct was abutted to a PMC1-DTa negative-selection cassette and linearized.
The linearized targeting construct was introduced by electroporation into C57BL/
6-derived Bruce4 recombinant embryonic stem cell and neomycin-resistant clones
were ﬁrst screened for homologous recombination by PCR utilizing a pair of the
following oligonucleotides corresponding to a sequence outside of the 50 left arm
and to the EGFP site: Primer 1: 50-GAGTACCTTCTAGGTCTATGTGA
CTTGACT-30 , and Primer 2: 50-ATATAGACGTTGTGGCTGTTGTAGTTGT
A-30 . EcoRV-digested genomic DNA of positive clones was then screened by
Southern blotting with a 30 external single-copy probe corresponding to a
0.507-kb fragment (Supplementary Fig. 3f), which was ampliﬁed by PCR using
the oligonucleotides 50-TTGGTGAAAATTAAAATCACATTCA-30 and
50- TGGCATTATAATTAGCTGACACTGA-30 . When tested on EcoRV-digested
DNA, it hybridized either to a 8.3-kb WT fragment or to a 7.6-kb recombinant
fragment. Embryonic stem cell clones bearing the correctly targeted locus were
injected into BALB/c blastocysts, and chimeric male offspring, in which the
autodeleter cassette was self-excised during the male germline transmission, were
mated with female C57BL/6 mice to obtain heterozygotes, which were then crossed
to obtain homozygotes. Transmission of the targeted allele was conﬁrmed by PCR
with Primer 1 and Primer 2 as described above. CRE-mediated deletion of the
ﬂoxed Neor cassette can be visualized by the presence of a 6.3-kb fragment using
EcoRV-digested DNA hybridized with the 30 external single-copy probe as
described above. The mutant mice were cross-mated for more than nine
generations with C57BL/6 mice, and 8- to 12-week-old female Clec4a4þ /þ
littermates were used as WT mice.
Cell isolation. To prepare single-cell suspensions from spleen, PLNs and MLNs,
tissue samples were digested with collagenase type III (Worthington Biochemical)
at 37 C for 20min, and were ground between glass slides. Splenocytes were treated
with red blood cell lysis buffer (Sigma-Aldrich) before suspension. BM cells were
ﬂushed from the femurs and tibias. Single-cell suspensions were obtained by
forcing through a 100-mm cell strainer (BD Biosciences). CD4þ T cells and CD8þ
T cells were puriﬁed from the spleen with mouse CD4 T-lymphocyte Enrichment
Set-DM and mouse CD8 T-lymphocyte Enrichment Set-DM (both from BD
Biosciences). CD11cþ DCs were puriﬁed by AutoMACS with mouse CD11c
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Figure 5 | Deﬁciency of Clec4A4 leads to TLR-mediated hyperinﬂammatory response in vivo. (a) WTmice (n¼6) and Clec4a4 / mice (n¼6) were
injected with LPS, and serum production of cytokines was measured at the indicated time after injection by ELISA. Data are the mean±s.d. from six
individual samples in a single experiment. *Po0.01 compared with WTmice (analysis of variance (ANOVA), Bonferroni’s multiple comparison test). (b,c)
WTmice (n¼ 10) and Clec4a4 / mice (n¼ 10) were injected with heat-killed E. coli. (b) Survival rate was monitored at the indicated times for 60 h after
injection of heat-killed E. coli. *Po0.01 compared with WTmice (Kaplan–Meier log-rank test). (c) Serum production of cytokines was measured 24 h after
injection with heat-killed E. coli by ELISA. Data are the mean±s.d. from 10 individual samples in a single experiment. *Po0.01 compared with WTmice
(analysis of variance (ANOVA), Bonferroni’s multiple comparison test). All data are representative of at least three independent experiments.
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(N418) Microbeads (Miltenyi Biotec). For the preparation of CD11chighCD8a
cDCs, splenocytes were depleted of T cells, B cells and granulocytes with
biotin-conjugated Ab cocktail and anti-biotin Microbeads from CD4þ Dendritic
Cell Isolation kit (Miltenyi Biotec) according to the manufacturer’s directions
with some modiﬁcations, and then subjected to puriﬁcation using mouse CD11c
(N418) Microbeads. In some experiments, CD11cþ DCs were sorted into
CD11chighCD8a cDCs with high purity (each 499%) using a FACSAriaII cell
sorter (BD Biosciences) with ﬂuorescein-conjugated mAbs. BMDCs were generated
by culturing BM cells with granulocyte–macrophage colony-stimulating factor
(GM-CSF, 20 ngml 1, Wako Pure Chemical Industries) for 8 days40,41.
Retrovirus-mediated gene transfer. Total RNA from CD8a cDCs (106)
was extracted with TRIzol (Life Technologies), and cDNA was synthesized with
oligo(dT)20 as a primer using the SuperScript III First-Strand Synthesis System
for RT–PCR kit (Life Technologies). The full-length cDNA of C terminus
FLAG-tagged Clec4a4 (NCBI: AY397673) was ampliﬁed by PCR using GoTaq
Green Master Mix (Promega) with a pair of speciﬁc primers (50-CGCGGA
TCCGCCGCCATGGCTTCAGAAATC-30 and 50-CGCCTCGAGTCACTTGTC
ATCGTCGTCCTTGTAGTCTAAGTATATTTTCTT-30). Each of the 50 and 30
primers was also tagged (indicated in italics) with BamH1 and XhoI sites, while
kosac sequence or FLAG sequence was indicated with an underline or an underline
in italics. The PCR product was subcloned into pCR4-TOPO using TA TOPO
Cloning Kit for Sequencing (Life Technologies) and the nucleotide sequence was
conﬁrmed with an ABI3100xl automated sequencer (Applied Biosystems) and the
ﬂuoresceinated dye terminator cycle sequencing method. Alternatively, the DNA
sequence of Clec4A4DI5–V10, Clec4A4DY68–L236 or Clec4A4N186Q, which were
tagged with BamH1 and XhoI sites in 50 and 30 terminals, was custom-made using
GeneArt (Life Technologies). After restriction enzyme digestion, the DNA
sequence was cloned into the sites of the pMX-IRES-GFP vector41,42, and was
transfected into a retroviral packaging cell line, Phoenix41,42, with LipofectAMINE
Plus Reagent (Life Technologies). The culture supernatant of Phoenix after 24 h of
culture was collected and centrifuged at 8,000g for 16 h at 4 C to concentrate the
virus. The retroviral vector was transfected into BM for the generation of BM-DCs
as described above or DC2.4 cell lines together with DOTAP Liposomal
Transfection Reagent (Roche) by centrifugation at 2,000g for 1 h at 32 C, and
transfectants were subsequently collected to examine GFP expression by using
FACSAriaII cell sorter.
Generation of human IgG Fc fusion protein. The DNA sequences containing the
extracellular domain lacking the signal sequence and intracellular domain of
Clec4a4 (NCBI: AAR31149 amino acids: 68–236) were custom-made using
GeneArt, and the 50 and 30 ends of the synthesized DNA sequences were also
tagged with EcoRI and BglII sites, respectively. After restriction enzyme digestion,
the synthesized DNA sequence was cloned into the sites of pFUSE-hIgG2-Fc2
(Invivogen), and transfected into FreeStyle 293-F cells (Life Technologies)
using 293fectin Transfection Reagent (Life Technologies) according to the
manufacturers’ instructions. huIgFc or Clec4A4-huIgFc fusion protein
was puriﬁed from the culture supernatant using HiTrap Protein G HP
(GE Healthcare Life Sciences), and the puriﬁed fusion protein was separated by
10% SDS–PAGE under non-reducing or reducing conditions, respectively, and
stained with a Silver Stain kit (Bio-Rad Laboratories) to conﬁrm the protein
products.
Flow cytometry. Cells were stained with ﬂuorescein-conjugated mAbs (1:100)
to mouse CD3e (cat#553066, 145-2C11), CD4 (cat#553046, RM4-5), CD8a
(cat#553032, 53-6.7), CD11c (cat#550261, HL3), CD40 (cat#553723, 3/23),
CD44 (cat#559250, IM7), CD45.1 (cat#558701, A20), CD49b (cat#553857, DX5),
CD80 (cat#553768, 16-10A1), CD86 (cat#553691, GL1), I-A/I-E (cat#557000,
M5/114.15.2), B220 (cat#553089, RA3-6B2), H-2Kb (cat#553569, AF6-88.5), Va2
TCR (cat#553289, B20.1), IFN-g (cat#554411, XMG1.2), IL-17A (cat#559502,
TC11-18H10), isotype-matched control mAb (cat#550003/559940, 187.1; BD
Biosciences), dendritic cell marker (cat#12-5884, 33D1; eBioscience), CD11b
(cat#101206, M1/70; Biolegend), Siglec-H (cat#130-102-229, JF05-1C2.4.1;
Miltenyi Biotec), and H-2Kb OVA tetramer (cat#TS-5001-1C; MBL). For the
intracellular expression of cytokines, cells were incubated for 4 h with phorbol
12-myristate 13-acetate (50 ngml 1; Sigma-Aldrich) plus ionomycin
(500 ngml 1; Sigma-Aldrich) or OVA257–264 peptide (SIINFEKL; 10mM) plus
GolgiPlug (BD Biosciences) during the ﬁnal 2 h. Subsequently, the cells were
resuspended in Fixation-Permeabilization solution (BD Cytoﬁx/Cytoperm kit; BD
Biosciences) and intracellular cytokine staining was carried out according to the
manufacturer’s directions. For staining with recombinant fusion proteins, cells
were stained with huIgFc (1 mg), Clec4A4-huIgFc (1 mg), SIGNR1-huIgFc
(cat#1836-SR, 1 mg), or Clec9A-huIgFc (cat#6049-CL, 1 mg; both from R&D
Systems) followed by anti-human IgG-PE (cat#12-4998-82; eBiosciences).
Fluorescence staining was analysed with a FACSCalibur ﬂow cytometer and
CELLQuest Software (both from BD Biosciences).
Culture of CD11cþ DCs. CD11chighCD8a cDCs were cultured with or without
Pam3CSK4 (1 mgml 1), poly(I:C) (50 mgml 1), LPS (1 mgml 1), or CpG-B
(0.1 mM) for 18 h in 48-well culture plates (BD Bioscience). Similarly, BMDCs
expressing mock-GFP, Clec4A4-GFP, Clec4A4N186Q-GFP, Clec4A4DY68–L236-GFP,
or Clec4A4DI5–V10-GFP were cultured with or without LPS (1 mgml 1) or CpG-B
(0.1 mM) for 18 h in 48-well culture plates. Alternatively, DC2.4, DC2.4-expressing
mock-GFP or DC2.4-expressing Clec4A4-GFP (5 105) were cultured with or
without Pam3CSK4 (1 mgml 1), poly(I:C) (50 mgml 1), LPS (0.1mgml 1), or
CpG-B (0.1 mM) for 18 h in 48-well culture plates. The culture supernatants were
collected and stored at  80 C until assayed for cytokines.
Detection of cytokines. Culture supernatants and sera were assayed for IFN-b
(PBL), TNF-a, IL-6, IL-12p40 (eBioscience), IL-17A and IFN-g (Biolegend) using
enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers’
instructions.
Immunoblotting. DC2.4, DC2.4-expressing mock-GFP and DC2.4-expressing
Clec4A4-GFP (2 106) were stimulated or not stimulated with LPS (0.1 mgml 1)
for the period indicated. Alternatively, BMDCs expressing mock-GFP or
Clec4A4-GFP as well as CD8a cDCs (2 106) were stimulated or not stimulated
with LPS (1 mgml 1) or CpG-B (1mgml 1) for the period indicated. Total lysate
was analysed by SDS–PAGE, and blots were probed with Ab (1:1,000) for NF-kB
p65 (cat#8242, D4E12), ERK (cat#9102), JNK (cat#9252), p38 (cat#9212), IRF-3
(cat#4302, D83B9) (Cell Signaling Technology) and IRF-7 (cat#sc-9083, H-246;
Santa Cruz Biotechnology) or the phosphospeciﬁc Ab (1:1,000) for NF-kB p65
(cat#3033, 93H1), ERK (cat#9101), JNK (cat#9251), p38 (cat#9211), IRF-3
(cat#4947, 4D4G) and IRF-7 (cat#14767; Cell Signaling Technology) followed by
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (cat#7074, 1:1,000;
Cell Signaling Technology). In some experiments, BMDCs expressing mock-GFP
or Clec4A4-GFP as well as DC2.4, DC2.4-expressing mock-GFP and
DC2.4-expressing Clec4A4-GFP (2 106) were pretreated with or without the
cross-linked anti-FLAG M2 mAb (cat#F1804, 10 mgml 1; Sigma-Aldrich) with
secondary goat anti-rabbit IgG (cat#111-005-003, 100 mgml 1; Jackson
ImmunoResearch) for 30min. Then, cells were stimulated or not stimulated
with LPS (1 mgml 1) or CpG-B (1 mgml 1) for 30min. Subsequently, the
immunoprecipitate with anti-FLAG M2 mAb (F1804, 1:100), anti-SHP-1 mAb
(cat#sc-30810, G-20, 1:100) or anti-SHP-2 mAb (cat#sc-280, C-18, 1:100)
Figure 6 | Deﬁciency of Clec4A4 increases Ag-speciﬁc CD4þ T-cell responses in vivo. (a–d) CD45.1þOT-II CD4þ T cells were cultured with CD8a
cDCs obtained from WTmice and Clec4a4 / mice in the presence or absence of Pam3CSK4 (1mgml 1), poly(I:C) (50 mgml 1), LPS (1mgml 1) or
CpG-B (0.1mM) in combination with OVA323–339 peptide under TH1 (a,b)- or TH17 (c,d)-polarized culture conditions for 3 days, and intracellular production
of IFN-g (a,b) or IL-17 (c,d) in the cultured CD4þ Tcells was analysed by ﬂow cytometry. (a,c) Data are presented by a dot plot, and numbers represent the
proportion of IFN-gþ cells (a) and IL-17þ cells (c) among gated CD4þ Tcells in each quadrant. (b,d) Data are the mean percentage of positive cells±s.d.
from three individual samples in a single experiment. (e,f) CFSE-labelled CD45.1þOT-II CD4þ T cells were transferred into WTmice (n¼6) and
Clec4a4 / mice (n¼6), and then the mice were immunized with OVA protein in combination with or without the indicated TLR ligands. Ag-speciﬁc
division of CD45.1þOT-II CD4þ T cells was analysed 3 days after the immunization by ﬂow cytometry. (e) Data are presented by a histogram, and
numbers represent the proportion of CFSE dilution among gated CD45.1þOT-II CD4þ T cells in each histogram. (f) Data are the mean percentage of
positive cells±s.d. from six individual samples in a single experiment. (g–i) WTmice (n¼ 6) and Clec4a4 / mice (n¼6) were immunized with CFA plus
OVA protein. At 14 days after the immunization, spleen CD4þ Tcells were isolated then cultured with WTCD11cþ DCs in the presence or absence of OVA
protein for the measurement of proliferative responses by [3H]thymidine incorporation (g, left panel) and production of IFN-g (g, right panel) by ELISA.
Data are the mean±s.d. from six individual samples in a single experiment. (h,i) Intracellular production of IFN-g in the cultured CD4þ T cells was
analysed by ﬂow cytometry. (h) Data are presented by a dot plot, and numbers represent the proportion of IFN-gþ cells among gated CD4þ Tcells in each
quadrant. (i) Data are the mean percentage of positive cells±s.d. from six individual samples in a single experiment. *Po0.01 compared with WTmice
(analysis of variance (ANOVA), Bonferroni’s multiple comparison test). All data are representative of at least three independent experiments.
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(Santa Cruz Biotechnology) obtained from total cell lysate was analysed by
SDS–PAGE, and blots were probed with anti-phosphotyrosine (p-Tyr) mAb
(cat#sc-7020, PY99, 1:1,000; Santa Cruz Biotechnology) followed by HRP-con-
jugated goat anti-mouse IgG (cat#1031-05, 1:1,000; SouthernBiotech), anti-FLAG
M5 mAb (cat#1031-05, 1:1,000; Sigma-Aldrich), anti-SHP-1 mAb (cat#3759,
C14H6, 1:1,000) or anti-SHP-2 mAb (cat#3397, D50F2, 1:1,000) (Cell Signaling
Technology) followed by HRP-conjugated goat anti-rabbit IgG (cat#7074). The
blot was visualized by ChemiDoc XRSþ Image System (BIO-RAD) with an ECL
Plus Western Blotting Detection System (GE Healthcare). Images have been
cropped for presentation. Full-size images are presented in Supplementary Figs 11,
12,13 and 14.
SHP assay. Analysis of protein tyrosine phosphatase activity was described as
previously43. Brieﬂy, the immunoprecipitate with anti-FLAG M2 mAb (prepared
in lysis buffer without sodium orthovanadate) were incubated at 37 C for 30min
in 200 ml of phosphatase buffer (62mM HEPES, pH 5.0), 6.25mM EDTA and
12.5mM DTT) containing 25mM p-nitrophenylphosphate (Sigma-Aldrich).
Reactions were terminated by addition of 0.8ml of 1N NaOH, and the absorbance
measured at 410 nm by spectrophotometry.
Immunohistochemical analysis. Spleen was embedded in OCT compound
(Sakura Finetechnical) and frozen in liquid N2. The tissue segments were sectioned
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with a cryostat at 8 mm. Frozen sections were ﬁxed in cold acetone and blocked in
TNB buffer (PerkinElmer Life Science) containing 5% normal rat serum. To block
endogenous biotin, the sections were further treated with the Streptavidin/Biotin
Blocking Kit (Vector Laboratories), and endogenous peroxidase activity was
quenched with 1% H2O2. The primary Abs were anti-CD19-FITC mAb
(cat#553785, 1D3; BD Biosciences), anti-mouse dendritic cell marker-biotin mAb
(cat#130-101-843, 33D1; Miltenyi Biotec), anti-CD11c mAb-biotin mAb
(cat#553800, HL3; BD Biosciences) and anti-CD3e-APC mAb (cat#100312, 145-
2C11; Biolegend). The CD19 signal was ampliﬁed by incubation with Alexa Fluor
488-conjugated anti-rat IgG (cat#A11006; Life Technologies). The 33D1 and
CD11c staining was revealed with a TSA signal ampliﬁcation kit (PerkinElmer Life
Science) according to the manufacturer’s instructions. The sections were incubated
with Streptavidin-HRP (PerkinElmer Life Science) followed by Tyramide-Cy3
conjugate. At the end of the staining, slides were washed and mounted with
Vectashield (Vector Laboratories). The stained slides were examined with a
BIOREVO ﬂuorescence microscope (BZ-9000; KEYENCE).
Glycan binding assay. The preparation of NGLs constructed with oligosacchar-
ides (Man3, LNFP3, LNT and GlcNAc) and DPPG, asialo-GM2, and
lactocerebrosides were described as previously23. For glycan binding assay, NGLs,
asialo-GM2, and lactocerebrosides dissolved in isopropanol (100 pM) were coated
to the wells of the ELISA plate, and the wells were dried at 37 C, and washed with
PBS. After blocking with 1% BSA (Fraction V, Sigma-Aldrich) in PBS for 1 h at
room temperature, huIgFc, Clec4A4-huIgFc, SIGNR1-huIgFc or Clec9A-huIgFc
(5 mgml 1) was added to the wells of the ELISA plate for at least 2 h at room
temperature. After extensive washing with PBS, HRP-conjugated goat anti-human
IgG (Fc speciﬁc; cat#A0170, 1:20,000; Sigma-Aldrich) was added to the wells.
The reaction was developed with 3,30 ,5,50-tetramethylbenzidine as a substrate
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Figure 7 | Deﬁciency of Clec4A4 promotes Ag-speciﬁc CD8þ T-cell responses in vivo. (a,b) CFSE-labelled CD45.1þOT-I CD8þ Tcells were transferred
into WTmice (n¼6) and Clec4a4 / mice (n¼ 6), and then the mice were immunized with OVA protein in combination with or without the indicated
TLR ligands. Ag-speciﬁc division of CD45.1þOT-I CD8þ Tcells was analysed 3 days after the immunization by ﬂow cytometry. (a) Data are presented by a
histogram, and numbers represent the proportion of CFSE dilution among gated CD45.1þOT-I CD8þ T cells in each quadrant. (b) Data are the mean
percentage of positive cells±s.d. from six individual samples in a single experiment. (c–f) WTmice (n¼6) and Clec4a4 / mice (n¼ 6) were
immunized with the indicated TLR ligands, anti-CD40 mAb, and OVA protein. At 6 days after the immunization, splenocytes were analysed for the
generation of MHC I-OVA tetramerþCD44highCD8þ T cells (c,d) and for intracellular IFN-g-producing CD8þ T cells (e,f) by ﬂow cytometry.
Data are presented by a dot plot (c,e) and numbers represent the proportion of MHC I-OVA tetramerþCD44high cells (c) and IFN-gþ cells (e) among
gated CD8þ T cells in each quadrant. (d,f) Data are the mean percentage of positive cells±s.d. from six individual samples in a single experiment.
*Po0.01 compared with WTmice (analysis of variance (ANOVA), Bonferroni’s multiple comparison test). All data are representative of at least three
independent experiments.
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(Sigma Aldrich), and the absorbance was measured at 450 nm by microplate reader
(iMark, BIO-RAD).
Ag presentation assay. CD45.1þOT-I CD8þ T cells (105) or CD45.1þOT-II
CD4þ T cells (105) were cultured with the irradiated (15Gy) CD8a cDCs
(1.25 103–104) in the presence of OVA257–264 peptide (1 pM–1 nM) or
OVA323–339 peptide (ISQAVHAAHAEINEAGR; 1 nM–1 mM) for 3 days in 96-well
ﬂat-bottomed plates. Alternatively, CD4þ T cells (2 105) were cultured with
irradiated (15Gy) CD11cþ DCs (2 104) in the presence or absence of OVA
protein (1mgml 1, Sigma-Aldrich) or MOG35–55 peptide (MEVGWYRSPFSR
VVHLYRNGK; 1 mM) for 3 days in 96-well ﬂat-bottomed plates (BD Biosciences).
[3H]thymidine (GE Healthcare) incorporation was measured on day 3 for the last
18 h. In another experiment, the cells and the culture supernatants were collected to
detect the production of cytokines.
In vivo TLR stimulation. Mice were intraperitoneally (i.p.) injected with
Pam3CSK4 (20 mg per mouse), poly(I:C) (50mg per mouse), LPS (10 mg per mouse)
or CpG-B (10 mg per mouse), and sera were collected at the indicated times.
In some experiments, spleen was obtained from the mice 24 h after injection.
Model for bacterial peritonitis. For bacterial peritonitis38, mice were injected i.p.
with heat-killed (95 C for 30min) E. coli (DH5a, Life Technologies; 5 107
per mouse). Survival was monitored at the indicated times for 60 h after injection
and sera were collected 24 h after injection.
In vitro CD4þ T-cell differentiation assay. For the differentiation of TH1 cells44,
CD45.1þOT-II CD4þ T cells (2 105) were cultured with CD8a cDCs
(2 104) in the presence or absence of Pam3CSK4 (1.25–1 mgml 1), poly(I:C)
(12.5–50mgml 1), LPS (0.25–1 mgml 1) or CpG-B (0.025–0.1 mM) in
combination with OVA323–339 peptide (1 mM), anti-IL-4 mAb (10 mgml 1;
11B11, BD Biosciences) and recombinant mouse IL-2 (0.2 ngml 1; Wako Pure
Chemicals) for 3 days in 96-well ﬂat-bottomed plates. For the differentiation of
TH17 cells44, CD45.1þOT-II CD4þ T cells (2 105) were cultured with
CD8a cDCs (2 104) in the presence or absence of TLR ligands as described
above in combination with OVA323–339 peptide (1mM), anti-IFN-g mAb
(10 mgml 1; R4-6A2, BD Biosciences), anti-IL-4 mAb (10 mgml 1; 11B11),
recombinant mouse IL-2 (0.2 ngml 1) and recombinant human transforming
growth factor-b1 (10 ngml 1; Wako Pure Chemicals) for 3 days in 96-well
ﬂat-bottomed plates. Analysis of the expression of IFN-g or IL-17 among gated
CD4þ T cells was performed by ﬂow cytometry as described above.
*
0
5
10
15
20
25
30
Po
si
tiv
e 
ce
lls
 (%
)
WT
CD4+IL-17+T cells
CD4+IFN-γ+T cells
*
*
302826242220181614121086420
0
25
50
75
100
Days after immunization
WT
Clec4a4 –/–
In
ci
de
nc
e 
of
 E
AE
 (%
)
302826242220181614121086420
0
1
2
3
4
Days after immunization
WT
Clec4a4 –/–
M
ea
n 
cl
in
ic
al
 s
co
re
**
**
*
*
*
*
IFN-γ
4.2 10.5
4.6
WT
Clec4a4 –/–
23.7IL
-1
7
0.3
3.5
1.2
5.6
0.1
3.1
3.7
9.1
None MOGp
*
0
20
40
60
80
*
0
300
600
900
1,200
1,500 None
MOGp
None
MOGp
None
MOGp
0
500
1,000
1,500
2,000
*
*
0.01
0.1
1
10
[3 H
] th
ym
idi
ne
 up
tak
e
(×1
0–
2 )
IF
N
-γ
 
(pg
 m
l–1
)
IL
-1
7 
(pg
 m
l–1
)
Cle
c4a
4
–
/–
WT
Cle
c4a
4
–
/–
WT
Cle
c4a
4
–
/–
WT
Cle
c4a
4
–
/–
WT
Clec4a4 –/–
MO
Gp
No
ne
MO
Gp
No
ne
α
M
O
G
p 
Ig
G
 (m
g m
l–1
)
CD4+IFN-γ+IL-17+T cells
a b
c d e
f g
Figure 8 | Deﬁciency of Clec4A4 aggravates EAE. WTmice (n¼ 10) and Clec4a4 / mice (n¼ 10) were immunized with CFA plus MOGp. (a,b) The
disease severity of each mouse was scored, and mean clinical score±s.d. (a) and disease incidence (b) at the indicated times were plotted from 10
individual mouse in a single experiment. (c–f) At 14 days after the immunization, Spl CD4þ Tcells were cultured with WT CD11cþ DCs in the presence or
absence of MOGp for the measurement of proliferative responses by [3H]thymidine incorporation (c) and production of IFN-g (d, left panel) and IL-17
(d, right panel) by ELISA. Data are the mean±s.d. from 10 individual samples in a single experiment. (e,f) Intracellular production of IFN-g and IL-17 in the
cultured CD4þ Tcells was analysed by ﬂow cytometry. (e) Data are presented by a dot plot, and numbers represent the proportion of IFN-gþ cells and IL-
17þ cells among gated CD4þ T cells in each quadrant. (f) Data are the mean percentage of positive cells±s.d. from 10 individual samples in a single
experiment. (g) Serum MOGp-speciﬁc IgG production was measured at 22 days after immunization by ELISA. Data are the mean±s.d. from 10 individual
samples in a single experiment. *Po0.01 compared with WTmice (analysis of variance (ANOVA), Bonferroni’s multiple comparison test). All data are
representative of at least three independent experiments.
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Adoptive transfer. CD45.1þOT-I CD8þ T cells or CD45.1þOT-II CD4þ
T cells were labelled with CFSE (Molecular Probes; 2.5 mM) at 37 C for 10min,
and washed twice with cold PBS. Subsequently, CFSE-labelled CD45.1þOT-I
CD8þ T cells or CD45.1þOT-II CD4þ T cells (5 106 per mouse) were
intravenously injected into mice 24 h before the i.p. injection with or without OVA
protein (50 mg per mouse) in combination with or without Pam3CSK4 (20mg
per mouse), poly(I:C) (50 mg per mouse), LPS (10mg per mouse) or CpG-B
(10 mg per mouse). After 1–3 days, the gated CD45.1þOT-I CD8þ T cells and
CD45.1þOT-II CD4þ T cells in the spleen were analysed for CFSE dilution to
detect the dividing cells by ﬂow cytometry.
Immunization. For the analysis of Ag-speciﬁc CD4þ T-cell responses, mice were
immunized subcutaneously (s.c.) with OVA protein (100 mg per mouse) emulsiﬁed
in CFA (Difco) or OVA protein (100 mg per mouse) plus CpG-B (50 mg per mouse)
and the spleen was obtained 14 days after the immunization. For the generation of
antigen-speciﬁc CTLs6,24,45, mice received an i.p. injection of Pam3CSK4 (20 mg
per mouse), poly(I:C) (50 mg per mouse), LPS (10 mg per mouse) or CpG-B (10 mg
per mouse) in combination with an i.p. injection of OVA protein (500 mg per
mouse) plus of anti-CD40 mAb (10 mg per mouse; 1C10; eBioscience) and the
spleen was obtained from the mice 3–9 days later.
EAE induction. Mice were immunized s.c. with MOG35–55 peptide (200 mg per
mouse, BEX) emulsiﬁed in CFA (500 mg of H37Ra) on day 0 and pertussis toxin
(500 ng, CALBIOCHEM) i.p. on day 0 and again on day 2. Clinical scores were as
follows: tail weakness, grade 1; hind limb weakness, grade 2; partial hind limb
paralysis and weight loss, grade 3; paraplegia and incontinence, grade 4;
quadriplegia and wasting, grade 5; and moribund, grade 6. In another experiment,
mice were killed on day 14 after immunization to obtain the spleen. In some
experiments, sera were obtained on day 22 after immunization, and assayed for
MOG35–55 peptide-speciﬁc IgG46 using ELISA kits (ANASpec) according to the
manufacturer’s instructions.
Bacteria and infection. LM-OVA were grown in brain–heart infusion broth
(Merck). For bacterial infections6,24, mice were i.p. infected with LM-OVA
(5 105 c.f.u. per mouse). Survival was then monitored for 15 days or serum
samples were collected 6 days after infection. For the determination of bacterial
burden, splenic growth of LM-OVA was quantiﬁed by plating serial dilutions of
homogenates on Oxford-Listeria-Selective-Agar (Merck) 6 days after infection, and
the colonies were counted after an overnight incubation at 37 C. In some
experiments, the spleen was obtained from mice 6 days after infection.
Statistical analysis. Data are expressed as the mean±s.d. The statistical sig-
niﬁcance of the differences between the values obtained was evaluated by one-way
analysis of variance with Bonferroni’s multiple comparison post-test and the
Kaplan–Meier log-rank test. A P value of o0.01 was considered signiﬁcant.
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